The three major forms of treatment for Graves thyrotoxicosis are antithyroid drugs, radioactive iodine therapy and thyroidectomy. Surgery is the definitive treatment for Graves thyrotoxicosis that is generally recommended when other treatments have failed or are contraindicated. Generally, thyrotoxic patients should be euthyroid before surgery to minimize potential complications which usually requires preoperative management with thionamides or inorganic iodine. But several cases of refractory Graves' disease have shown resistance to conventional treatment. Here we report a 40-year-old female patient with Graves' disease who complained of thyrotoxic symptoms for 7 months. Her thyroid function test and thyroid autoantibody profiles were consistent with Graves' disease. One kind of thionamides and β-blocker were started to control her disease. However, she was resistant to nearly all conventional medical therapies, including β-blockers, inorganic iodine, and two thionamides. She experienced hepatotoxicity from the thionamides. What was worse is her past history of serious allergic reaction to corticosteroids, which are often used to help control symptoms. A 2-week regimen of high-dose cholestyramine improved her uncontrolled thyrotoxicosis and subsequent thyroidectomy was successfully performed. In conclusion, cholestyramine could be administered as an effective and safe adjunctive agent for preoperative preparation in patients with severe hyperthyroid Graves's disease that is resistant to conventional therapies.

Citations

Citations to this article as recorded by  

• Enhanced predictive validity of integrative models for refractory hyperthyroidism considering baseline and early therapy characteristics: a prospective cohort study
  Xinpan Wang, Tiantian Li, Yue Li, Qiuyi Wang, Yun Cai, Zhixiao Wang, Yun Shi, Tao Yang, Xuqin Zheng
  Journal of Translational Medicine.2024;[Epub]     CrossRef
• Non-thionamide antithyroid drug options in Graves’ hyperthyroidism
  Aliya Ruslan, Onyebuchi E Okosieme
  Expert Review of Endocrinology & Metabolism.2023; 18(1): 67.     CrossRef
• Gestione clinica dell’ipertiroidismo refrattario
  Daniela Gallo, Federica Martina Bianchi, Francesca Manzella La Barbera, Ilaria Clementi, Adriana Lai, Eliana Piantanida, Maria Laura Tanda
  L'Endocrinologo.2023; 24(2): 167.     CrossRef
• Carbimazole-Resistant Grave’s Thyrotoxicosis is a Diagnostic and Therapeutic Dilemma, Case Report with Literature Review
  Fateen Ata, Adeel Ahmad Khan, Shuja Tahir, Zaina Al Amer
  International Medical Case Reports Journal.2023; Volume 16: 783.     CrossRef
• Medical treatment of thyrotoxicosis
  Lorenzo SCAPPATICCIO, Giuseppe BELLASTELLA, Maria I. MAIORINO, Luca GIOVANELLA, Katherine ESPOSITO
  The Quarterly Journal of Nuclear Medicine and Molecular Imaging.2021;[Epub]     CrossRef
• THERAPEUTIC EFFECTS OF COMBINATION REGIMENS INCLUDING METHIMAZOLE ON GRAVES HYPERTHYROIDISM: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
  Maorong Wang, Yerong Yu
  Endocrine Practice.2020; 26(6): 675.     CrossRef
• Cholestyramine alters bile acid amounts and the expression of cholesterol‐related genes in rabbit intestinal and hepatic tissues
  Dong Ni Qiu, Quan Shang, Da Yu Sun, Wei Qun Ding, Zhong Guang Luo, Jian Chen, Wei Ru Jiang, Jian Ping Huang, Xiao Yun Jiang
  Journal of Digestive Diseases.2017; 18(2): 107.     CrossRef
• ENDOCRINOLOGY IN PREGNANCY: Pregnancy and the incidence, diagnosing and therapy of Graves’ disease
  Peter Laurberg, Stine Linding Andersen
  European Journal of Endocrinology.2016; 175(5): R219.     CrossRef
• 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis
  Douglas S. Ross, Henry B. Burch, David S. Cooper, M. Carol Greenlee, Peter Laurberg, Ana Luiza Maia, Scott A. Rivkees, Mary Samuels, Julie Ann Sosa, Marius N. Stan, Martin A. Walter
  Thyroid.2016; 26(10): 1343.     CrossRef
• Cholestyramine Use for Rapid Reversion to Euthyroid States in Patients with Thyrotoxicosis
  Jeonghoon Ha, Kwanhoon Jo, Borami Kang, Min-Hee Kim, Dong-Jun Lim
  Endocrinology and Metabolism.2016; 31(3): 476.     CrossRef
• The role of bile acids in metabolic regulation
  Libor Vítek, Martin Haluzík
  Journal of Endocrinology.2016; 228(3): R85.     CrossRef
• Recent Advances in Autoimmune Thyroid Diseases
  Won Sang Yoo, Hyun Kyung Chung
  Endocrinology and Metabolism.2016; 31(3): 379.     CrossRef
• A Case of Methimazole-Resistant Severe Graves' Disease: Dramatic Response to Cholestyramine
  Seung Byung Chae, Eun Sook Kim, Yun Im Lee, Bo Ram Min
  International Journal of Thyroidology.2016; 9(2): 190.     CrossRef

Distant metastases from papillary thyroid carcinoma (PTC) are rare and are associated with a poor prognosis. Here, we describe a patient with metastatic PTC who was treated with a tyrosine kinase inhibitor (TKI, sorafenib) for several months that was acutely exacerbated by discontinuation. A 43-year-old male was diagnosed with PTC in February 2004 and underwent total thyroidectomy followed by two courses of high-dose radioactive iodine (RAI) therapy. Despite two additional courses of high-dose RAI therapy, lung and muscle metastases were developed. Treatment with sorafenib was begun in September 2010. After 11 months treatment of sorafenib, newly developed metastatic lesions were found in mediastinal lymph nodes, liver, and bones. Considered as treatment failure, the administration of sorafenib was discontinued. Two weeks after sorafenib treatment was stopped, the disease progressed abruptly and caused death of the patient by respiratory failure. In our patient, PTC progressed rapidly after the cessation of sorafenib treatment. Patients with several other types of cancer have also experienced such rapid disease progression, termed "flare-ups." Physicians should be aware that flare-ups may occur in advanced PTC patients following the cessation of TKI therapy.

Citations

Citations to this article as recorded by  

• Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer
  Silvia Martina Ferrari, Giusy Elia, Francesca Ragusa, Sabrina Rosaria Paparo, Valeria Mazzi, Mario Miccoli, Maria Rosaria Galdiero, Gilda Varricchi, Rudy Foddis, Giovanni Guglielmi, Claudio Spinelli, Concettina La Motta, Salvatore Benvenga, Alessandro Ant
  Expert Opinion on Investigational Drugs.2021; 30(9): 913.     CrossRef
• Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma – A Real-World Experience
  He-Jiun Jiang, Yen-Hsiang Chang, Yen-Hao Chen, Che-Wei Wu, Pei-Wen Wang, Pi-Jung Hsiao
  Cancer Management and Research.2021; Volume 13: 7139.     CrossRef
• Rapid disease progression after discontinuation of lenvatinib in thyroid cancer
  Haruhiko Yamazaki, Kiminori Sugino, Kenichi Matsuzu, Chie Masaki, Junko Akaishi, Kiyomi Hames, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Munetaka Masuda, Koichi Ito
  Medicine.2020; 99(11): e19408.     CrossRef
• Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application
  Rosa Maria Paragliola, Andrea Corsello, Valeria Del Gatto, Giampaolo Papi, Alfredo Pontecorvi, Salvatore Maria Corsello
  Expert Opinion on Drug Discovery.2020; 15(1): 11.     CrossRef
• Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences
  Chie Masaki, Kiminori Sugino, Naoko Saito, Junko Akaishi, Kiyomi Y. Hames, Chisato Tomoda, Akifumi Suzuki, Kenichi Matsuzu, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Koichi Ito
  Thyroid.2020; 30(2): 214.     CrossRef
• Papillary thyroid carcinoma with hyperthyroidism and multiple metastases
  Li-li Zhang, Bin Liu, Fang-fang Sun, Hong-yu Li, Shuang Li, Li-rong Zhao
  Medicine.2020; 99(30): e21346.     CrossRef
• Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma
  Leszek Herbowski
  Diagnostics.2020; 10(7): 457.     CrossRef
• Reply to “Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma”
  Liviu Hitu, Calin Cainap, Dragos Apostu, Katalin Gabora, Eduard-Alexandru Bonci, Marius Badan, Alexandru Mester, Andra Piciu
  Diagnostics.2020; 10(7): 458.     CrossRef
• Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro
  Min-Hee Kim, Tae Hyeong Lee, Jin Soo Lee, Dong-Jun Lim, Peter Chang-Whan Lee
  Pharmaceuticals.2020; 13(9): 208.     CrossRef
• Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study
  Hye-Seon Oh, Dong Yeob Shin, Mijin Kim, So Young Park, Tae Hyuk Kim, Bo Hyun Kim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Dong Jun Lim, Won Gu Kim
  Thyroid.2019; 29(12): 1804.     CrossRef
• Rapid pleural effusion after discontinuation of lenvatinib in a patient with pleural metastasis from thyroid cancer
  Taisuke Uchida, Hideki Yamaguchi, Kazuhiro Nagamine, Tadato Yonekawa, Eriko Nakamura, Nobuhiro Shibata, Fumiaki Kawano, Yujiro Asada, Masamitsu Nakazato
  Endocrinology, Diabetes & Metabolism Case Reports.2019;[Epub]     CrossRef
• Thyroid Disorders in the Elderly
  Kevin Higgins
  Clinics in Geriatric Medicine.2018; 34(2): 259.     CrossRef
• Treatment of refractory thyroid cancer
  Amandine Berdelou, Livia Lamartina, Michele Klain, Sophie Leboulleux, Martin Schlumberger, _ _
  Endocrine-Related Cancer.2018; 25(4): R209.     CrossRef
• Clinical guidance for radioiodine refractory differentiated thyroid cancer
  Matti L. Gild, Duncan J. Topliss, Diana Learoyd, Francis Parnis, Jeanne Tie, Brett Hughes, John P. Walsh, Donald S.A. McLeod, Roderick J. Clifton‐Bligh, Bruce G. Robinson
  Clinical Endocrinology.2018; 88(4): 529.     CrossRef
• Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients
  Thomas J. Smith, Nasser Hanna, David Johnson, Sherman Baker, William A. Biermann, Julie Brahmer, Peter M. Ellis, Giuseppe Giaccone, Paul J. Hesketh, Ishmael Jaiyesimi, Natasha B. Leighl, Gregory J. Riely, Joan H. Schiller, Bryan J. Schneider, Joan Tashbar
  Journal of Oncology Practice.2017; 13(12): 780.     CrossRef
• Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports
  Paul S. White, Anita Pudusseri, Stephanie L. Lee, Omar Eton
  Thyroid.2017; 27(9): 1201.     CrossRef
• Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report
  Fabiana Pani, Elisabetta Macerola, Fulvio Basolo, Francesco Boi, Mario Scartozzi, Stefano Mariotti
  Oncology Letters.2017; 14(2): 2186.     CrossRef
• Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare
  Terumi Tanigawa, Shintaro Morisaki, Hisanobu Fukuda, Shuichiro Yoshimura, Hisayoshi Nakajima, Kohei Kotera
  Case Reports in Obstetrics and Gynecology.2017; 2017: 1.     CrossRef
• Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung
  Mijin Kim, Won Gu Kim, Suyeon Park, Hyemi Kwon, Min Ji Jeon, Jong Jin Lee, Jin-Sook Ryu, Tae Yong Kim, Young Kee Shong, Won Bae Kim
  Thyroid.2017; 27(1): 49.     CrossRef
• Articles in 'Endocrinology and Metabolism' in 2014
  Won-Young Lee
  Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
• Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography
  Justine Yang Bruce, Peter Colin Scully, Lakeesha L. Carmichael, Jens C. Eickhoff, Scott B. Perlman, Jill Marie Kolesar, Jennifer L. Heideman, Robert Jeraj, Glenn Liu
  Cancer Chemotherapy and Pharmacology.2015; 76(1): 187.     CrossRef
• Optimal Differentiated Thyroid Cancer Management in the Elderly
  Donald S. A. McLeod, Kelly Carruthers, Dev A. S. Kevat
  Drugs & Aging.2015; 32(4): 283.     CrossRef